Dr. David Sidransky Appointed Director of Champions Biotechnology, Inc.
Arlington, VA – August 14, 2007 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a development stage biotechnology company, announced today the appointment of Dr. David Sidransky, Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine, to serve on the Company’s Board of Directors. Dr. Sidransky is the largest shareholder of Champions Biotechnology.
Dr. Sidransky, 47, is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Dr. Sidransky is one of the five most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents.
Dr. Sidransky has served as Vice Chairman of the Board of Directors, and presently is a director of ImClone (IMCL). He is a Vice Chairman of Alfacell (ACEL) and serves on the Board of Directors of Xenomics (XNOM). He is serving and has served on scientific advisory boards of MedImmune (MEDI), Roche, Amgen (AMGN) and Veridex, LLC (a Johnson & Johnson diagnostic company), among others.
Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer Research (AACR). He was the chairperson of the first (September 2006) and is the chairperson of the second (September 2007) AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment.
Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research.
“We are very pleased and delighted to announce that Dr. David Sidransky has been appointed to serve as a Director of the Company” said James Martell, Chairman, CEO and President of Champions Biotechnology. “Dr. Sidransky is a creative, out-of-the box thinker with wide-ranging academic and business background and extensive contacts with the pharmaceutical industry, academia and government. His depth and breadth of experience will be invaluable to us.”
Champions Biotechnology is actively engaged in pursuit of additional opportunities to grow and strengthen the company.